By Andrea Golan
Dec 19, 2023
In our second blog in a series of Vicente Insights discussing hemp regulation under the new Minnesota Cannabis Law, we break down Minnesota’s regulation of “synthetic cannabinoids” including how they are defined, when they can be used, and whether the rules for synthetic cannabinoids differ for cannabis and hemp.
By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Dec 13, 2023
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #6 focuses on updates from the recent subcommittee meetings and the full meeting of the Natural Medicine Advisory Board.
By Jason Adelstone
Dec 7, 2023
On October 27, 2023, the Ninth Circuit Court of Appeals, in Aggarwal v. DEA, held that the U.S. Drug Enforcement Agency (DEA) must reconsider its denial of a petition to transfer psilocybin, the active ingredient in “magic mushrooms” from Schedule I to Schedule II. Read this Insights post for more information about the Ninth Circuit Court’s order to reschedule psilocybin.
By Andrea Golan
Nov 16, 2023
In this first post in a series of Vicente Insights discussing hemp regulation under the new Minnesota cannabis law, we will dive into the licenses and endorsements required to cultivate, process, manufacture, transport, and sell hemp ingredients and hemp products.
By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Nov 14, 2023
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #5 focuses on updates from the October subcommittee meetings and the full meeting of the Natural Medicine Advisory Board.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.
